Table 2 Cohort characteristics for human organoid-based studies [related to Figs. 4 and 5A, Main Text].

From: Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease

Internal number (UC San Diego HUMANOID)

% TEER increase after PF, normalized to untreated (Average from 3–5 experiments)

Disease location; Disease behavior

Drug history

Disease duration (years)

Disease scorea SES

Healthy H4

52.1

n/a

n/a

n/a

n/a

Healthy H9

17.5

n/a

n/a

n/a

n/a

Healthy H12

9

n/a

n/a

n/a

n/a

Healthy H13

6.8

n/a

n/a

n/a

n/a

UC1

30

Pancolitis

Current Adalimumab

9

8

UC2

100

Left sided colitis

Only ASA

21

9

UC3

62

Left sided colitis

Infliximab (just started)

3

6

UC13

187.5

Proctitis

Vedolizumab

0.28

5

CD2

37

Ileocolitis

Current Remicade

2.8

Unk

CD3

18

Ileitis

Current Humira

3

Unk

CD10

49.45

Ileitis; Non-stricturing, non-penetrating

Current Adalimumab Past infliximab

23

8

CD11

55.5

Ileocolitis; Stricturing

Past Vedolizumab, Past Adalimumab

19

6

CD20

47.3

Ileitis; Non-stricturing, non-penetrating

Current Adalimumab

1

0

CD24

15.3

Colitis; Stricturing

Current Vedolizumab

6

0

CD30

377.5

Ileitis; Non-stricturing, non-penetrating

Naive

18

0

CD21

211.4

Colitis; Non-stricturing; non-penetrating

Current Infliximab

1

8

CD32

52.9

Ileocolitis; Penetrating

Current Infliximab

20

3

CD42

3.3

Ileocolitis; Penetrating

Past Infliximab

12

4

  1. In 18 human subjects in the cohort, 11 are Male, 7 are Female from the following age group: below 20 years: 3; 21–40 years: 10; above 40 years: 5.
  2. Diseased Cohort (N = 14).
  3. Increase in TEER less than ≤25% N = 3 of 14; 21.42% (all CD).
  4. Increase in TEER within >25–75%, N = 7 of 14; 50% (5 CD, 2 UC).
  5. Increase in TEER is above >75%, N = 4 of 14; 28.57% (2 CD, 2 UC).
  6. Unk unknown; n/a not available.
  7. aDisease Score: UC: Histo Geboes Score, CD: SES-CD score/Disease score.
Back to article page